Repligen Co. (NASDAQ:RGEN) Holdings Lifted by Rhumbline Advisers

Rhumbline Advisers grew its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 1.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 146,149 shares of the biotechnology company's stock after acquiring an additional 2,739 shares during the period. Rhumbline Advisers owned 0.26% of Repligen worth $21,037,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Ballentine Partners LLC increased its holdings in Repligen by 4.0% in the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock valued at $270,000 after purchasing an additional 72 shares during the period. MML Investors Services LLC raised its holdings in shares of Repligen by 2.7% in the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company's stock worth $503,000 after acquiring an additional 89 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock worth $98,000 after acquiring an additional 90 shares during the last quarter. Louisiana State Employees Retirement System raised its holdings in shares of Repligen by 0.7% in the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock worth $2,087,000 after acquiring an additional 100 shares during the last quarter. Finally, UMB Bank n.a. increased its stake in Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after buying an additional 110 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Repligen Stock Performance

Shares of NASDAQ:RGEN traded down $3.68 during trading on Friday, hitting $158.99. 795,356 shares of the stock traded hands, compared to its average volume of 609,046. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $203.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a fifty day moving average price of $155.22 and a two-hundred day moving average price of $148.79. The company has a market cap of $8.91 billion, a price-to-earnings ratio of -429.69, a P/E/G ratio of 4.23 and a beta of 0.99.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analysts' expectations of $167.58 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. As a group, equities analysts predict that Repligen Co. will post 1.54 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on RGEN shares. TD Cowen started coverage on shares of Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 price target for the company. Canaccord Genuity Group lifted their price objective on shares of Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a report on Friday. Wolfe Research assumed coverage on shares of Repligen in a report on Thursday, November 14th. They set a "peer perform" rating for the company. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research report on Friday, January 3rd. Finally, HC Wainwright restated a "buy" rating and issued a $180.00 price objective on shares of Repligen in a research report on Friday. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $183.36.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.